|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases. |
| 公司地址
| 55 Cambridge Parkway, Suite 6W, Cambridge, MA, USA, 02142 |
| 電話號碼
| +1 617 682-0917 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.amylyx.com |
| 員工數量
| 136 |
| Mr. James M. Frates |
Chief Financial Officer and Principal Accounting Officer |
美元 540.60K |
23/04/2026 |
| Dr. Camille L. Bedrosian,M.D. |
Chief Medical Officer |
美元 575.00K |
23/04/2026 |
| Mr. Joshua B. Cohen |
Co-Chief Executive Officer and Director |
美元 686.20K |
23/04/2026 |
| Mr. Justin B. Klee |
Co-Chief Executive Officer and Director |
美元 686.20K |
23/04/2026 |
| Ms. Gina M. Mazzariello |
Chief Legal Officer and General Counsel |
-- |
23/04/2026 |
|
|
| Dr. George Mclean Milne, Jr,PhD |
Chairman of the Board |
23/04/2026 |
| Dr. Bernhardt G. Zeiher, F.A.C.P.,F.C.C.P.,M.D. |
Independent Director |
23/04/2026 |
| Ms. Daphne E. Quimi |
Independent Director |
23/04/2026 |
| Mr. Paul Fonteyne, M.S. |
Independent Director |
23/04/2026 |
| Ms. Karen Firestone |
Independent Director |
23/04/2026 |
| Mr. Joshua B. Cohen |
Co-Chief Executive Officer and Director |
23/04/2026 |
| Mr. Justin B. Klee |
Co-Chief Executive Officer and Director |
23/04/2026 |
|
|
|
|
